Bladder Cancer Treatment

Data Up to Date as of:

On This Page:

In 2019, 35.5% of patients with non-muscle invasive disease received intravesical therapy.

Summary graph for Bladder Cancer Treatment, Click to see detailed view of graph

See Graph Details

Background

Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. The first targeted therapy for bladder cancer was approved by the FDA in 2019. Treatment options depend on the stage of bladder cancer. Four types of standard treatment are used: surgery, radiation therapy, chemotherapy, and immunotherapy. Intravesical (within the bladder) therapy, one type of immunotherapy, involves the instillation of an agent or biologic into the bladder. The use of intravesical therapy has been associated with improved survival for individuals with non-muscle invasive bladder cancer. There have been no significant increases in the use of intravesical therapy for patients diagnosed with non-muscle invasive in the most recent time period, while use of intravesical therapy has increased significantly in the most recent time period for those diagnosed with muscle-invasive and metastatic disease. The Ta G1-2 means non-invasive papillary carcinoma (Ta) that is Grade 1 (well differentiated) or Grade 2 (moderately differentiated). There have been no significant increases in the use of systemic therapy for patients diagnosed with non-muscle invasive in the most recent time period, while use of systemic therapy has increased significantly in the most recent time period for those diagnosed with muscle-invasive and metastatic disease.

Measure

Percentage of individuals receiving intravesical therapy.

Percentage of individuals receiving systemic therapy.

Healthy People 2030 Target

  • There are no Healthy People 2030 targets for cancer treatment, including bladder cancer treatment.

Healthy People 2030 is a set of goals set forth by the Department of Health and Human Services.

Data Source

SEER Patterns of Care/Quality of Care Studies, National Cancer Institute, 1995-2019.

Trends and Most Recent EstimatesHelp with navigating the graphs and data tables

Intravesical Therapy

Percent of bladder cancer patients receiving intravesical therapy by extent of disease, 1995-2019
Overview Graph Detailed Trend Graphs Most Recent Estimates (2019)
Percent of patients 95% Confidence Interval
Thumbnail of graph for Percent of bladder cancer patients receiving intravesical therapy by extent of disease, 1995-2019 Ta G1-2Click to see the detailed trend graph for Ta G1-2 35.5 30.7 - 40.7
Other non-muscle invasive diseaseClick to see the detailed trend graph for Other non-muscle invasive disease 64.6 60.3 - 68.6
Muscle invasive/metastatic diseaseClick to see the detailed trend graph for Muscle invasive/metastatic disease 28.3 22.5 - 35.0

Systemic Therapy

Percent of bladder cancer patients receiving systemic therapy by extent of disease, 1995-2019
Overview Graph Detailed Trend Graphs Most Recent Estimates (2019)
Percent of patients 95% Confidence Interval
Thumbnail of graph for Percent of bladder cancer patients receiving systemic therapy by extent of disease, 1995-2019 Ta G1-2Click to see the detailed trend graph for Ta G1-2 0.7 0.3 - 1.7
Other non-muscle invasive diseaseClick to see the detailed trend graph for Other non-muscle invasive disease 9.2 7.1 - 11.9
Muscle invasive/metastatic diseaseClick to see the detailed trend graph for Muscle invasive/metastatic disease 48.7 42.1 - 55.3

Additional Information on Bladder Cancer Treatment

Year Range

1995-2019

Recent Summary Trend Year Range

2009-2019

Summary Tables

Bladder, Breast, Colorectal

Recent Summary Trend

Non-Significant Change

Desired Direction

Rising